Recombinant human erythropoietin in the treatment of acute ischemic stroke.

@article{Ehrenreich2009RecombinantHE,
  title={Recombinant human erythropoietin in the treatment of acute ischemic stroke.},
  author={Hannelore Ehrenreich and Karin Weissenborn and Hilmar Prange and Dietmar Schneider and Christian Weimar and Katja Elfriede Wartenberg and Peter Dieter Schellinger and Matthias Bohn and Harald Alexander Becker and Martin Wegrzyn and Peter Jaehnig and Manfred Herrmann and Michael Knauth and M. B{\"a}hr and Wolfgang Heide and Armin Wagner and S. Prexler Schwab and Heinz Reichmann and Guenther Schwendemann and R. Dengler and Andreas Kastrup and Claudia Bartels},
  journal={Stroke},
  year={2009},
  volume={40 12},
  pages={
          e647-56
        }
}
BACKGROUND AND PURPOSE Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recent studies have identified increased thromboembolic complications and/or mortality risks on EPO administration to patients with cancer or chronic kidney disease. Accordingly… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 285 CITATIONS, ESTIMATED 48% COVERAGE

To my readers

VIEW 7 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

The Science of Stroke: Mechanisms in Search of Treatments

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1992
2019

CITATION STATISTICS

  • 20 Highly Influenced Citations

  • Averaged 11 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES